Drug Trial Radar · NCT07460232
FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Apr 27, 2026
Primary completion
Apr 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 10, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research is to evaluate the performance \[sensitivity, specificity, accuracy\] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
Conditions
- Cushing Disease
- Pituitary Adenoma
Interventions
Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PETDrug
Patients will receive intravenous administration of radiolabeled FET (5mCi ±10%) administered 20 minutes (±10minutes) prior to the initiation of the attenuation correction CT followed by the PET acquisition encompassing the participant's head/neck, centered on the pituitary gland.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity of FET PET results in comparison to histopathologyTime frame: Baseline
- Specificity of FET PET results in comparison to histopathologyTime frame: Baseline
- Accuracy of FET PET results in comparison to histopathologyTime frame: Baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.